Deals Of The Week Gets Better Connected, Dips A Toe In Digital Health
This article was originally published in The Pink Sheet
Executive Summary
Digital health promises to transform the quality of health care and reduce costs, but it is not quite yet in a position to help out governments and other payers struggling to meet the demands put on their health care systems. Plus, news of deals between AstraZeneca and Roche, MorphoSys and Celgene, Aspen and Merck, and more.
You may also be interested in...
GSK Negotiating Potential $1 Billion Sale Of Two Thrombosis Drugs To Aspen
Reflecting its aim to jettison older products with declining sales, GlaxoSmithKline is considering an offer from South Africa-based generics maker Aspen Pharmacare for its branded heart medicines Arixtra and Fraxiparine and a related manufacturing site in France.
Deals Of The Week Looks At How Amgen’s Global Expansion Affects Partnering
Plus perspectives on AstraZeneca/Pearl Therapeutics, Xenon/Isis, Questcor/Novartis, BMS/Simcere and more.
Deals Of The Week: Janssen/CorImmun, AstraZeneca/Cellworks, Ferring/Albireo
To the familiar sounds of the Fourth of July and mid-summer, Deals of the Week adds another: the sound of the next shoe dropping in biopharmaceutical merger-and-acquisition activity. What happens next after the $5 billion-plus buyout of Amylin by Bristol-Myers?